Categories: Market Research

Global Enzyme Inhibitor Market Size and Forecast 2024-2033|Abbott Laboratories, Amgen Inc., AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG

The coronavirus 3CL hydrolase enzyme is essential for the maturation of the virus. It can be a promising target for drugs that would inhibit cleavage of the viral polyprotein and prevent spread of the infection. Source: PDB entry 6LU7

The Enzyme Inhibitor by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Enzyme Inhibitor Market:

https://www.thebusinessresearchcompany.com/report/enzyme-inhibitor-global-market-report

According to The Business Research Company’s Enzyme Inhibitor , The enzyme inhibitor market size has grown steadily in recent years. It will grow from $180.38 billion in 2023 to $186.04 billion in 2024 at a compound annual growth rate (CAGR) of 3.1%. The growth in the historic period can be attributed to increased demand for enzyme inhibitors in the treatment of various diseases, advancements in drug discovery and development, growing prevalence of chronic diseases, increased geriatric population, rising awareness about the benefits of enzyme inhibitors.

The enzyme inhibitor market size is expected to see steady growth in the next few years. It will grow to $216.75 billion in 2028 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to growing investment in research and development activities, increasing demand for personalized medicine, rising incidence of chronic diseases in emerging markets, growing demand for enzyme inhibitors in the treatment of cancer, expansion of applications in rare and genetic diseases. Major trends in the forecast period include development of reversible and irreversible enzyme inhibitors, exploration of natural products as sources of enzyme inhibitors, integration of computational methods in enzyme inhibitor discovery, emphasis on personalized dosing and treatment regimens, expansion of enzyme inhibitor applications in oncology and neurodegenerative diseases.

The rise in the incidence of diseases including cancer is expected to propel the growth of the enzyme inhibitor market going forward. Enzymes, such as telomerase, which is active in most tumor cells, are utilized to cure cancers, including leukemia, and also keep healthy adult cells from becoming cancerous. For instance, in January 2022, according to the American Cancer Society, a US-based non-profit healthcare group dedicated to cancer elimination, on average in the US, 1,670 individuals are going to die from cancer every day in 2022, with 1.9 million cases being diagnosed and 609,360 fatalities. Therefore, the rise in the incidence of diseases such as cancer is driving the demand for the enzyme inhibitor market growth.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=6728&type=smp

The enzyme inhibitor market covered in this report is segmented –

1) By Type: Proton Pump Inhibitors (PPIs), Protease Inhibitors, Reverse Transcriptase Inhibitors, Aromatase Inhibitors, Kinase Inhibitors, Neuraminidase Inhibitors, Statins, Other Types

2) By Disease Indication: Chronic Obstructive Pulmonary Disorders, Cardiovascular Disease, Gastrointestinal Disorders, Arthritis, Inflammatory Diseases, Other Disease Indications

3) By Application: Chemotherapy, Antibiotics, Pesticides, Cardiovascular Treatments, Other Applications

4) By End User: Pharmaceutical, Biotechnology, Food and Beverage, Other End Users

Strategic partnerships and collaborations have emerged as a key trend gaining popularity in the enzyme inhibitor market. Major companies operating in enzyme inhibitors are focused on strategic partnerships to meet customer demand. For instance, in April 2021, Artios Pharma Limited, a UK-based DNA damage response company that also provides enzyme inhibitors, collaborated with Novartis International AG, a Switzerland-based pharmaceutical corporation, to uncover and verify new generation DDR (DNA Damage Response) targets to advance Novartis’ Radioligand Therapies (RLT). This partnership with Novartis will be utilized to find and validate next-generation DDR targets to improve Novartis’ radioligand therapies.

The enzyme inhibitor market report table of contents includes:

1. Executive Summary

2. Enzyme Inhibitor Market Characteristics

3. Enzyme Inhibitor Market Trends And Strategies

4. Enzyme Inhibitor Market – Macro Economic Scenario

5. Global Enzyme Inhibitor Market Size and Growth

26. South America Enzyme Inhibitor Market

27. Brazil Enzyme Inhibitor Market

28. Middle East Enzyme Inhibitor Market

29. Africa Enzyme Inhibitor Market

30. Enzyme Inhibitor Market Competitive Landscape And Company Profiles

Top Major Players: